Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials.
about
Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XLVariation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatmentRapid antidepressant effects: moving right alongEfficacy, tolerability, and acceptability of bupropion for major depressive disorder: a meta-analysis of randomized-controlled trials comparison with venlafaxineKetamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacyComparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patientsReward processing in autism: a thematic series.Loss of NMDA receptors in dopamine neurons leads to the development of affective disorder-like symptoms in mice.Association study of phosphodiesterase genes in the Sequenced Treatment Alternatives to Relieve Depression sample.A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?Pharmacogenetics of major depression: insights from level 1 of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial.Treatment goals of depressed outpatients: a qualitative investigation of goals identified by participants in a depression treatment trialUse of antidepressants: expansion beyond depression and anxiety.Strategies to improve the management of depression in primary care.Reconsidering anhedonia in depression: lessons from translational neuroscience.Estrogens of multiple classes and their role in mental health disease mechanisms.Convergent evidence from mouse and human studies suggests the involvement of zinc finger protein 326 gene in antidepressant treatment response.Glutamatergic modulators: the future of treating mood disorders?Advances in the treatment of depressionGlycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics.A review of treating depression in diabetes: emerging findings.Leptin receptor deficiency confers resistance to behavioral effects of fluoxetine and desipramine via separable substrates.Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area.CYP2C19 variation and citalopram response.Ketamine and the next generation of antidepressants with a rapid onset of actionCatechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response.Impact of pretreatment with antidepressants on the efficacy of duloxetine in terms of mood symptoms and functioning: an analysis of 15 pooled major depressive disorder studies.Toward achieving optimal response: understanding and managing antidepressant side effectsNovel glutamatergic agents for major depressive disorder and bipolar disorder.Pilot randomized clinical trial of an SSRI vs bupropion: effects on suicidal behavior, ideation, and mood in major depressionA Preliminary Study: Efficacy of Mindfulness-Based Cognitive Therapy versus Sertraline as First-line Treatments for Major Depressive Disorder.Hypersomnia in Mood Disorders: a Rapidly Changing LandscapeImproved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report.Rapid Antidepressant Response with Ketamine: Is it the Solution to Resistant Depression?From Randomized Controlled Trials of Antidepressant Drugs to the Meta-Analytic Synthesis of Evidence: Methodological Aspects Lead to Discrepant FindingsStereoselective Glucuronidation of Bupropion Metabolites In Vitro and In VivoPersonality and differential treatment response in major depression: a randomized controlled trial comparing cognitive-behavioural therapy and pharmacotherapy.The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort.
P2860
Q21260321-AA91011F-BF9B-4B0D-AF26-2AD8C23BA7D4Q24530904-3A38280A-2E8D-478D-8FB0-E1264BDCF309Q24546379-BEBE285A-F618-41F0-9338-793A37839DC3Q24614410-9728949A-6583-4138-9D19-DCA366B78361Q26864531-95473117-59C4-43FC-B08C-2827E975DAD5Q27024227-7FF6B47A-4071-4279-BDFC-0B267F67FE19Q30411445-5F95308E-BE9E-4A52-92C9-0D6F0CFD48B0Q30449347-3221E133-6FF6-4D3B-B69C-F98E903C370DQ30462673-5E2B1652-7412-4B3D-908C-A6CDEF8FA850Q30828943-6D94C3F2-A35C-466C-9D08-1137DB63A91BQ33641417-97DFE1D1-20AE-4EDD-B2B3-BEC1DEC3A57CQ33718185-75DA4934-58DB-4DD2-8952-E0A9FAF53101Q33730306-92B2A2D2-A44F-47D8-BB45-8C3EC2EB1B66Q33806404-80410C30-8C60-4775-B3AD-5483D78F81A1Q33818027-41C4177F-2C3D-4CCE-8F41-0D8C59F91133Q34023777-210B1530-8A43-4DC4-A86D-3E3A84D2199DQ34124371-C5DC2424-889B-4DD3-A080-957A38041FE8Q34272184-66689B7A-51A1-43BF-BD0F-D0F9BDC49891Q34292369-8FCC3ED4-5235-4BD6-8626-0F8A04F6F289Q34398007-3AE4A95E-AEFD-46D0-B64B-35BA4E848F6CQ34496251-76B61321-9FEA-41CA-BA55-D64CA891345FQ34555598-43ED188D-DAAA-4DF9-8FD4-7CD5AC7CD94AQ34597335-FAFA88AE-ECED-4553-BA81-AB025D8581ECQ34731202-D4F61A16-45F1-4B5C-B5FB-FDEF9F948406Q34879739-EC3B362A-DF93-4FBB-A7B2-98BE8348D4E5Q34954026-CB08CDCD-C17B-486B-A887-1C0979DEDDADQ34978041-B6779BF6-A5B1-4F96-BB5E-2A69B979B517Q35040545-79FF7DE7-5CA2-4A9C-80E6-D67F819B99A3Q35061870-500A4EDA-ECD3-4B5A-A935-09A847F62069Q35237051-F7544FDD-48ED-4009-BED6-2D1E75996360Q35661119-80A11F12-3CEE-4706-AB08-38C59C428EADQ35679916-53BA05E0-24CD-4583-8C4D-45E5CCAD3684Q35737882-23F070A5-F30A-4912-B0CE-DC04D19CBCE4Q35920392-AED55573-96FE-4358-AB14-2A801265E56EQ35965584-12C1F847-3807-48E7-A15C-8DAAD31E2EE1Q35993160-D48C0E73-E965-4DEA-9FDE-88C5D5E68946Q36601436-9441C535-27DE-46C5-9D9E-56A6175EF78DQ36737009-B5056C4B-DB0C-4876-9B99-79C7622DAB30Q36892336-50956822-655B-4A15-AB5A-080636EC27A9Q36984013-EA5F1AE3-9B69-414E-9640-43503042A24C
P2860
Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Remission rates following anti ...... randomized controlled trials.
@ast
Remission rates following anti ...... randomized controlled trials.
@en
type
label
Remission rates following anti ...... randomized controlled trials.
@ast
Remission rates following anti ...... randomized controlled trials.
@en
prefLabel
Remission rates following anti ...... randomized controlled trials.
@ast
Remission rates following anti ...... randomized controlled trials.
@en
P2093
P1476
Remission rates following anti ...... randomized controlled trials.
@en
P2093
April E Harriett
Barbara R Haight
Carol B Rockett
Jack G Modell
Melinda Mitton
Michael E Thase
Nathalie Richard
Susan VanMeter
Younghua Wang
P304
P577
2005-08-01T00:00:00Z